Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this work, we provide a rationale for the finding that the estrogen receptor (ER) binds to its DNA response element as a homodimer in vivo. Binding of the monomer estrogen receptor DNA binding domain (ER
DBD
) to a palindromic, consensus estrogen response element (ERE) is increased 5-6-fold when the ER
DBD
is dimerized either by a monoclonal antibody that recognizes an attached epitope tag or by expressing the ER
DBD
as a single molecule in which the two monomers are joined by a peptide linker. Most of the increase in binding is due to stabilization of the ER
DBD
.ERE complex. We observed only an approximately 2.5-fold reduction in binding when a consensus ERE was replaced with widely spaced ERE half-sites, suggesting that the interaction between ER DBDs on the ERE is relatively weak, and that in full-length ER the DBDs can move independently of each other. To test binding to an imperfect palindrome, typical of the imperfect EREs found in almost all natural estrogen receptor responsive genes, we used the
pS2
ERE. Even at high concentrations of ER
DBD
, specific binding of the ER
DBD
to the imperfect
pS2
ERE was undetectable. Both of the dimerized ER DBDs exhibited efficient binding to the imperfect
pS2
ERE, with an affinity at least 25-fold greater than monomer ER
DBD
. These data support the view that steroid receptor dimerization provides an important mechanism facilitating the recognition of naturally occurring, imperfect hormone response elements.
...
PMID:Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements. 934 45